REGENXBIO PE Ratio 2014-2022 | RGNX
Current and historical p/e ratio for REGENXBIO (RGNX) from 2014 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. REGENXBIO PE ratio as of February 03, 2023 is 13.81.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| REGENXBIO PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-02-03 |
23.75 |
|
15.32 |
| 2022-09-30 |
26.43 |
$1.55 |
17.05 |
| 2022-06-30 |
24.70 |
$1.93 |
12.80 |
| 2022-03-31 |
33.19 |
$2.15 |
15.44 |
| 2021-12-31 |
32.70 |
$2.74 |
11.93 |
| 2021-09-30 |
41.92 |
$-5.17 |
0.00 |
| 2021-06-30 |
38.85 |
$-3.57 |
0.00 |
| 2021-03-31 |
34.11 |
$-3.12 |
0.00 |
| 2020-12-31 |
45.36 |
$-3.00 |
0.00 |
| 2020-09-30 |
27.52 |
$-2.48 |
0.00 |
| 2020-06-30 |
36.83 |
$-3.65 |
0.00 |
| 2020-03-31 |
32.38 |
$-2.78 |
0.00 |
| 2019-12-31 |
40.97 |
$-2.59 |
0.00 |
| 2019-09-30 |
35.60 |
$-1.76 |
0.00 |
| 2019-06-30 |
51.37 |
$-1.38 |
0.00 |
| 2019-03-31 |
57.31 |
$-1.04 |
0.00 |
| 2018-12-31 |
41.95 |
$2.89 |
14.52 |
| 2018-09-30 |
75.50 |
$2.27 |
33.26 |
| 2018-06-30 |
71.75 |
$2.16 |
33.22 |
| 2018-03-31 |
29.85 |
$1.39 |
21.47 |
| 2017-12-31 |
33.25 |
$-2.47 |
0.00 |
| 2017-09-30 |
32.95 |
$-2.70 |
0.00 |
| 2017-06-30 |
19.75 |
$-2.72 |
0.00 |
| 2017-03-31 |
19.30 |
$-2.80 |
0.00 |
| 2016-12-31 |
18.55 |
$-2.39 |
0.00 |
| 2016-09-30 |
14.01 |
$-1.85 |
0.00 |
| 2016-06-30 |
8.00 |
$-2.68 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.028B |
$0.470B |
|
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
|
